TipRanks
Advertisement
Advertisement
Adlai Nortye initiated with a Buy at Jefferies
PremiumThe FlyAdlai Nortye initiated with a Buy at Jefferies
1M ago
Adlai Nortye: Buy Rating Reiterated as RAS-Targeted Pipeline Advances; $20 Price Target Maintained
Premium
Ratings
Adlai Nortye: Buy Rating Reiterated as RAS-Targeted Pipeline Advances; $20 Price Target Maintained
1M ago
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035
Premium
Company Announcements
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035
1M ago
Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity
PremiumCompany AnnouncementsAdlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity
2M ago
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026
Premium
Company Announcements
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026
2M ago
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated
Premium
Ratings
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated
3M ago
Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained
PremiumRatingsAdlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained
3M ago
Adlai Nortye doses first patient in AN9025 trial
Premium
The Fly
Adlai Nortye doses first patient in AN9025 trial
3M ago
Cantor starts Adlai Nortye at Overweight, sees 180% upside
Premium
The Fly
Cantor starts Adlai Nortye at Overweight, sees 180% upside
4M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―